BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization potential and develop them through Phase Ia or IIb proof of concept, then sell them or find a partner to complete development outside of Taiwan or Asia.

BRIM seeks global rights to programs from academic groups, multinationals and biotechs. The company has four preclinical programs, including two cancer biologics and one dengue fever collaboration with a Johnson & Johnson unit.